As expected, treating TCR-T cells with a low dose of DAC (50 nM) during transduction, which were designated as dTCR-T cells, further enhanced their anti-leukemia capacity and cytokine secretion, and promoted the memory phenotype, which corresponded to an increased proportion of cytotoxic CD4+/CD8+ T cells and central memory CD45RO+CD62L+/CD45RO+CCR7+ T cells, respectively. Here, SELL is linked to leukemia.